Sharemaestro Newsreel

GT Biopharma Q2 Results: Net Loss Falls To $4.5 Million

GT Biopharma (NASDAQ: GTBP) reported a Q2 2026 net loss of $4.5 million, a significant improvement from the $30.2 million loss in Q2 2025, primarily due to the absence of a non-recurring $28.7 million Greenshoe liability from the prior year. However, operational losses widened …

TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord

TuHURA Biosciences presented its late-stage immuno-oncology pipeline at the Canaccord Genuity Growth Conference, detailing a Phase III study of IFx in Merkel cell carcinoma, a planned AML trial for its VISTA-inhibiting antibody, and preclinical work on immune-modulating antibody-drug conjugates. The company aims to address …

Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $37.56, Implies 16% Upside

Alto Neuroscience, Inc. (ANRO) has seen its average 12-month price target increased to $37.56 by 9 analysts, suggesting a 16% potential upside from its August 13 closing price. The consensus rating for the stock remains a "Buy" from 11 analysts.

Repligen Corp (RGEN) stake at 3.1% in new T. Rowe Price 13G/A

T. Rowe Price Associates, Inc. has filed an amended Schedule 13G/A, reporting a 3.1% beneficial ownership stake in Repligen Corp (RGEN), totaling 1,751,887 shares of common stock as of June 30, 2026. The filing indicates sole voting power over 1,744,549 shares and sole dispositive …

Armistice Capital (TMCI) discloses 6.36M-share Treace Medical ownership stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership stake of 6,364,000 shares in Treace Medical Concepts, Inc. (TMCI), representing 9.79% of the outstanding common stock. This ownership is held directly by Armistice Capital Master Fund Ltd., with Armistice Capital serving as …

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert for Replimune Group, Inc. (NASDAQ: REPL) regarding a securities class action lawsuit. Shareholders who purchased REPL shares between October 20, 2025, and April 10, 2026, are encouraged to contact the firm, as the complaint alleges …

Cabaletta Bio (CABA): T. Rowe Price reports 11.6% common stock stake

T. Rowe Price Investment Management, Inc. has reported an 11.6% ownership stake in Cabaletta Bio (CABA) common stock, amounting to 18,869,907 shares. The firm holds sole voting power over 18,776,448 shares and sole dispositive power over all 18,869,907 shares, explicitly denying beneficial ownership despite …

UnitedHealth Group Inc.: Target Price Consensus and Analysts Recommendations | UNH | US91324P1021

This article provides an overview of analyst recommendations and target price consensus for UnitedHealth Group Inc. (UNH). It details recent adjustments to price targets and ratings from various financial institutions like JPMorgan, Mizuho, and Morgan Stanley, largely maintaining or upgrading their outlooks. The consensus …

GeoVax Labs (GOVX): Armistice Capital and Steven Boyd disclose 4.99% stake

Armistice Capital, LLC and Steven Boyd have disclosed a 4.99% beneficial ownership stake in GeoVax Labs, Inc. (GOVX), as detailed in a recent SCHEDULE 13G/A SEC filing. This represents 387,038 shares of common stock with shared voting and dispositive power, as of June 30, …

bioAffinity Technologies prices $4M private placement offering

bioAffinity Technologies (NASDAQ:BIAF) has announced a private placement offering aiming to raise approximately $4.0 million. The company will sell 8,462,027 shares of common stock or pre-funded warrants, alongside warrants to purchase up to 16,924,054 shares, to an institutional investor. The offering is expected to …

T. Rowe Price (MEDP) discloses 7.2% Medpace Holdings stake in latest filing

T. Rowe Price Associates, Inc. has disclosed a 7.2% beneficial ownership stake in Medpace Holdings, Inc. (MEDP) through a SCHEDULE 13G filing. This represents 2,069,679 shares, with T. Rowe Price retaining sole voting power over 2,012,425 shares and sole dispositive power over all 2,069,679 …

T. Rowe Price Associates (DGX) discloses 5.43M Quest Diagnostics shares in 13G/A

T. Rowe Price Associates, Inc. filed an amended Schedule 13G, reporting a beneficial ownership of 5,428,244 shares, or 4.9% of Quest Diagnostics Inc. common stock. The firm holds sole voting power over 5,321,387 shares and sole dispositive power over all 5,428,244 shares, while explicitly …

T. Rowe Price Associates (RVTY) discloses 5.0% beneficial stake in Revvity

T. Rowe Price Associates has filed an amended Schedule 13G, disclosing a 5.0% beneficial ownership stake in Revvity Inc (RVTY) as of June 30, 2026. This amounts to 5,526,874 shares, with T. Rowe Price Associates holding sole voting power over 5,508,363 shares and sole …

Lifeward Ltd. 2026: Revenue $6.62M, Net income ($11.52M), EPS ($4.12) — 10-Q Summary

Lifeward Ltd. reported its 2026 quarterly results, showing a 15.7% year-over-year revenue increase to $6.62 million, driven by higher AlterG shipments and stronger ReWalk sales. Despite the revenue growth, the company recorded a net loss of ($11.52 million) and diluted loss per share of …

Replimune Group stock may move 5.6% on earnings release

Smith & Nephew GAAP EPS of $0.36, revenue of $1.6B

* Smith & Nephew press release [https://seekingalpha.com/filing/309951347] (SNN [https://seekingalpha.com/symbol/SNN]): Q2 GAAP EPS of $0.36. * Revenue of $1.6B (+3.2% Y/Y). * Trading profit for the first half reached $566M, an 8.10% increase year-over-year, expanding the trading profit margin by 60 bps to 18.30%. * …

Armistice Capital (KYNB) discloses 400,000-share, 9.88% Kyntra Bio position

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 400,000 shares of Kyntra Bio, Inc. common stock, which represents 9.88% of the class. Both parties share voting and dispositive power over these shares, held directly by Armistice Capital Master Fund Ltd. …

Lifeward (LFWD) Reports Q2 Loss, Misses Revenue Estimates

Candel Therapeutics (NASDAQ:CADL) Stock Price Down 4.6% After Earnings Miss

Candel Therapeutics (NASDAQ:CADL) stock fell 4.6% after reporting a quarterly loss of $0.52 per share, missing the consensus estimate of $0.27. Despite the earnings miss, management highlighted progress towards a biologics license application submission in Q4 and a first commercial product target for 2027. …

Armistice Capital (ICCM) reports 300,332 IceCure Medical shares under shared control

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 300,332 ordinary shares of IceCure Medical Ltd. (ICCM), representing 9.99% of the class, through a Schedule 13G SEC filing. These shares are held with shared voting and dispositive power. Armistice Capital acts as …

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Down on Disappointing Earnings

Is Privia Health Group (PRVA) A Bargain As Earnings Growth And Guidance Improve?

Alumis (NASDAQ:ALMS) Shares Gap Down After Earnings Miss

Alumis Inc. (NASDAQ:ALMS) experienced a significant share price drop after reporting disappointing earnings, missing both revenue and EPS consensus estimates. Despite the poor financial results and insider selling, analyst sentiment remains largely positive with a "Moderate Buy" consensus rating and a target price of …

Celcuity (NASDAQ:CELC) Shares Gap Down on Disappointing Earnings

Armistice Capital (VYGR) files 13G/A showing 3.44M Voyager Therapeutics shares

Armistice Capital discloses 4.99% VVOS position in Vivos Therapeutics (VVOS)

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff

The Gross Law Firm is alerting shareholders of Insulet Corporation (NASDAQ: PODD) about a lead plaintiff deadline of August 31, 2026, in a class action lawsuit. The lawsuit alleges that Insulet made materially false and/or misleading statements regarding defective manufacturing controls that created a …

U.S. Stock Futures Mixed, Heads for a Winning Week

Wall Street is headed for a winning week in which the S&P 500 has recorded a new all-time high. The Department of Commerce reported that retail sales decreased 0.6% in July. The Zacks Consensus Estimate was for a breakeven. The metric for June was …

Claritev (CTEV) Q2 2026 Earnings Call Transcript

Zoetis (ZTS) Remains a Leader, So Why Was It Sold?

Polen Capital Management Llc released its "Polen Focus Growth Strategy" Q2 2026 investor letter. A copy of the letter can be downloaded here. Polen Focus Growth returned 6.33% (net of fees) in the second quarter of 2026, significantly underperforming the Russell 1000 Growth Index's …

Vivos Therapeutics schedules Q2 2026 results, conference call

Vivos Therapeutics Inc (NASDAQ: VVOS) is set to release its second quarter 2026 financial results after market close on August 14, 2026. Following the release, the company will host a conference call at 5:00 pm ET to discuss the results, provide operational updates, and …

Lifeward (NASDAQ: LFWD) doubles H1 loss and warns on going concern as it adds debt

T. Rowe Price Associates (KMTS) discloses 4.97M Kestra Medical shares in 13G/A

T. Rowe Price Associates, Inc. has disclosed a beneficial ownership of 4,968,900 shares of Kestra Medical Technologies common stock, representing 8.5% of the class as of June 30, 2026. The firm holds sole voting power over 4,966,936 shares and sole dispositive power over all …

Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline

Harmony Biosciences reported record quarterly growth for its narcolepsy treatment WAKIX, which supports further investment in its pipeline. The company is advancing BP-205, an orexin 2 receptor agonist, with promising early data and plans for multiple Phase II studies. Additionally, Harmony is progressing Phase …

OCUL|Ocular Therapeutix Inc|Price:9.890|Chg%:-0.210

Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen